Multiple business lines are fully exerting efforts! Abbott Laboratories (ABT.US) Q2 revenue and profits exceed expectations, against the trend raised its 2026 full-year profit guidance.

After experiencing a better-than-expected second quarter, Abbott Laboratories (ABT.US) raised its profit guidance for 2026, largely due to improvements in most of its business lines. The financial report shows that Abbott Laboratories' second-quarter revenue was $12.59 billion, a 13.0% year-on-year increase, exceeding market expectations; adjusted earnings per share were $1.31, beating expectations by $0.03. In a statement released on Thursday, the company stated that it now expects adjusted earnings per share for the year to be between $5.45 and $5.60, with the median increasing by 5 cents; the company reaffirmed its full-year 2026 same-store sales growth expectations of 6.5% to 7.5%. Abbott Laboratories' medical devices and diabetes businesses slightly exceeded Wall Street's expectations. Its FreeStyle Libre 3 blood glucose sensor was previously linked to over 700 injuries and 7 deaths at the end of last year, as the device was found to provide inaccurate readings. The company is a major seller of infant formula and adult beverages (including protein drinks to combat weight loss drug side effects). Due to declining sales volumes and price adjustments implemented in the fourth quarter of 2025, the company's global nutritional product sales fell by about 3% year-on-year to $2.14 billion, but still exceeded analysts' forecasts of $2.12 billion. However, the performance of other business segments offset some of the impacts. Abbott Laboratories has been embroiled in litigation, with lawsuits alleging that its infant formula may cause necrotizing enterocolitis (NEC), a severe intestinal disease affecting premature babies. Additionally, a botulism outbreak has been plaguing startup formula manufacturers ByHeart Inc. and Nara Organics, both of which gained prominence when Abbott Laboratories' formula was recalled and caused a nationwide shortage in 2022. However, after Health and Human Services Secretary Robert F. Kennedy raised concerns about the safety of infant formula, the Food and Drug Administration (FDA) announced at the end of April that there were minimal heavy metals or pesticides found in U.S. formula supplies, boosting the confidence of formula manufacturers. The diagnostics business segment contributed $3.1 billion in revenue, a roughly 42% year-on-year increase, surpassing the market's expected $3 billion, largely due to the $919 million contribution from cancer diagnostics. In November of last year, Abbott Laboratories agreed to acquire cancer screening company Exact Sciences Corp., gaining tests such as Cologuard, which help screen for colorectal cancer - the second leading cause of cancer-related deaths in the United States.